

APC-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) (Site-specific conjugation) (0.03% Proclin)

Catalog # FM3-AY54A1



Source

APC-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) (FM3-AY54A1) is produced via site-specific conjugation of APC to Monoclonal Anti-FMC63 scFv Antibody, Mouse IgG1 under optimal conditions with a proprietary technology.

Isotype

Mouse IgG1/kappa

Specificity

Specifically recognizes the antigen-recognition domain of FMC63 derived CARs.

Conjugate

APC

Excitation Wavelength: 640 nm

Emission Wavelength: 661 nm

Application

Flow Cytometry (Evaluation of Anti-CD19 (FMC63 scFv) CAR Expression). Please note that this product is NOT compatible to streptavidin detection system.

Formulation

Lyophilized from 0.22 µm filtered solution in PBS, 0.5% BSA, 0.03% Proclin, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- 20°C to -70°C for 12 months in lyophilized state;
- 70°C for 12 months after reconstitution;
- 2-8°C for 12 months after reconstitution.

Bioactivity-FACS



5e5 of anti-CD19 CAR-293 cells were stained with 100 µL of 1:50 dilution (2 µL stock solution in 100 µL FACS buffer) of APC-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) (Cat. No. FM3-AY54A1) and isotype control antibody respectively. APC signal was used to evaluate the binding activity (QC tested).

Background

APC-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) (Site-specific conjugation) (0.03% Proclin)



Catalog # FMC63-AY54A1

FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. So far, most of reported CART19 trials contain the anti-CD19 scFv derived from FMC63, including the two FDA-approved CARs Kymriah and Yescarta.

Clinical and Translational Updates

Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.